BioWorld

March 22, 2005

View Archived Issues

Onyx, Bayer Plan To File NDA For Sorafenib On Interim Data

Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. plan to file for FDA approval of BAY 43-9006, which has been renamed sorafenib, based on interim Phase IIII data from a study in advanced kidney cancer patients. (BioWorld Today) Read More

Sequoia Raises $22M To Fund Programs In Viral Infections

Read More

Avastin Competitor Misses Endpoint; Genentech Jumps

Read More

Biolex Signs Up Centocor In Wide-Ranging Protein Deal

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More